Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up study of tofacitinib in rheumatoid arthritis
2006-005035-19Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability. Started Jan 2007; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-005035-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005035-19.